Shanghai Model Organisms Center Inc (688265) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Shanghai Model Organisms Center Inc stock ¥27.36, price ¥44.33, that is 38.3% below the price, quality 67 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
58‑month range ¥19.55 – ¥73.15 · fair‑value band ¥19.60 – ¥30.60 · the ¥44.33 price screens above the ¥27.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Shanghai Model Organisms Center in your weekly email
Every Wednesday you see whether Shanghai Model Organisms Center is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models.
Show moreShow less
The company uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene editing technology to introduce or delete target DNA fragments.
It offers toolbox of mice; disease mice, such as rare, infectious, and nervous system diseases, cardio-metabolic, autoimmune, and spontaneous tumor; and target humanized knockins, which includes tumor targets, immune checkpoint, complements, cytokines, and metabolic and other targets, as well as cytokine reporters, inducible cell ablation, and cell-specific reporters.
The company also provides other models comprising rats, such as humanized drug target, immunodeficient, diseases, reporters, and cre-drivers; standard strains including inbred and outbred; cells model, which includes reporter labeled, primary, wild-type, and other; and supporting solutions including colony management, such as cryopreservation and cryorecovery, housing and management, genotyping analysis, and breeding services, as well as auxiliary apparatuses, such as e-BLOT WB imaging system.
In addition, it offers model customization including includes gene editing technology, such as ES cell targeting, CRISPR gene editing, and transgene; genetically engineered type model, which includes conventional and conditional knockout; KO first, knock-in, point mutation, conditional point mutation, humanization, targeted conditional overexpression, and random transgene; and surgery and preconditioning.
Further, the company provides preclinical services, which includes non-GLP toxicology, pharmacokinetics, phenotype analysis, and pharmacology and pharmacodynamics. It offers treatment for various therapeutic areas, such as oncology; nervous system, autoimmune, and digestive system diseases.
The company was founded in 2000 and is headquartered in Shanghai, China.
Stock analysis
Shanghai Model Organisms Center Inc (688265) currently trades at ¥44.33, while our model-based Fair Value estimate is ¥27.36, 38% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥16.67 per share, and 0 of the 26 models we run sit above the ¥44.33 price.
Bear case: the Earnings-Based group reads lowest at ¥8.48, and 26 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥19.60 (bear) to ¥30.60 (bull), the price of ¥44.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Shanghai Model Organisms Center Inc reported revenue of 421M CNY in FY2025 versus 275M CNY in FY2021, a compound +11.2%/yr. Reported net income was 32.4M CNY in FY2025, compounding −14.6%/yr from FY2021.
Key figures
Market cap 3.3B CNY (≈ $501M) Small · P/E ratio 143.0 · P/S ratio 7.31 · EPS (TTM) ¥0.3100 · Dividend yield 0.3% · Net margin 4.9% · Return on equity 1.3% · Return on assets (EBIT) 0.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 43% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −38%, 688265 screens richer than that median.
Fair Value models
Bear¥19.60Fair Value ¥27.36Bull¥30.60
Price ¥44.33 · Downside -38.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.1586 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
Start year 2020 (pandemic). Over 10 years: +25.0% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−10.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.2%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−11.2% vs −7.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 7%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +25.4% a year for the price.
Compare Shanghai Model Organisms Center Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside−38.3% · Above median
Profitability
Return on equity (12 months)1.3% · Above median
Return on assets1.6% · Above median
Net margin (12 months)4.9% · Above median
Operating margin (12 months)−1.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)23.4% · Above median
Dividend yield (12 months)0.3% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai Model Organisms Center Inc Fair Value". https://www.fairvalue-calculator.com/stock/688265
Frequently asked questions
Is Shanghai Model Organisms Center Inc (688265) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥27.36 versus a price of ¥44.33, about 38% lower (overvalued).
What is the fair value of 688265?
Our model-based fair value for Shanghai Model Organisms Center Inc is ¥27.36 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥44.33.
What is the quality score of 688265?
Shanghai Model Organisms Center Inc has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Model Organisms Center Inc (688265)?
Our model-based price target is the fair value of ¥27.36 (as of Nov 7, 2026) from 26 valuation models. Cautious scenario ¥19.60, optimistic scenario ¥30.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Model Organisms Center Inc stock forecast for 2026?
Our models put fair value at ¥27.36, about 38% lower versus a price of ¥44.33 (overvalued). Cautious scenario ¥19.60, optimistic scenario ¥30.60. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Model Organisms Center Inc (688265)?
Shanghai Model Organisms Center Inc reported trailing-twelve-month revenue of about 458M CNY (latest available figure, as of Nov 7, 2026).
Does Shanghai Model Organisms Center Inc pay a dividend?
Shanghai Model Organisms Center Inc currently shows a dividend yield of 0.28% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Shanghai Model Organisms Center Inc (688265) and when is the ex-dividend date?
Shanghai Model Organisms Center Inc pays a dividend of ¥0.125 per share a year, a dividend yield of 0.3%. The last ex-dividend date was Jul 13, 2026. The payout ratio is 40.3% of earnings. Free cash flow covers the dividend 5.26 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Shanghai Model Organisms Center Inc (688265)?
For today's price to be fair in a discounted-cash-flow model, Shanghai Model Organisms Center Inc would have to grow free cash flow by +27.5 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.5 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 688265 use?
Our models discount Shanghai Model Organisms Center Inc at 10.4 %: a base by market capitalisation (small), damped by beta 0.30, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Model Organisms Center Inc that is +27.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Shanghai Model Organisms Center Inc (688265) delivered so far?
Over the past 5 years revenue at Shanghai Model Organisms Center Inc grew +16.5 % a year. The price currently implies free-cash-flow growth of +27.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shanghai Model Organisms Center Inc (688265) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Shanghai Model Organisms Center Inc (+27.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shanghai Model Organisms Center Inc (688265)?
The free-cash-flow yield on the price is 1.53 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Shanghai Model Organisms Center Inc produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shanghai Model Organisms Center Inc (688265)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Model Organisms Center Inc it is ¥27.36 per share (as of Nov 7, 2026), against a price of ¥44.33. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shanghai Model Organisms Center Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 688265 trades above its calculated fair value: price ¥44.33, fair value ¥27.36, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688265?
No. The price is what the market pays today (¥44.33); the fair value is what the company's own numbers justify (¥27.36). For Shanghai Model Organisms Center Inc the two are ¥16.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Model Organisms Center Inc worth?
The market values Shanghai Model Organisms Center Inc at about 3.3B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥44.33; our models calculate a fair value of ¥27.36 per share.
What do the bullish and bearish scenarios say about 688265?
Our models span a range for Shanghai Model Organisms Center Inc: cautious scenario ¥19.60, base ¥27.36, optimistic ¥30.60 per share (as of Nov 7, 2026, price ¥44.33). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688265?
Shanghai Model Organisms Center Inc trades at a price-to-earnings ratio of 143.0 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥27.36 is built from several models across several years. Other multiples: P/B 2.0, P/S 7.3.
How solid is the balance sheet of Shanghai Model Organisms Center Inc (688265)?
Balance-sheet figures for Shanghai Model Organisms Center Inc (as of Nov 7, 2026): return on equity 1.3%, debt of 0.01 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 688265 from its 52-week high?
Shanghai Model Organisms Center Inc trades at ¥44.33, about 32% below its 52-week high of ¥64.98 and 43% above the low of ¥31.03 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥27.36 is for.
Which stocks are comparable to Shanghai Model Organisms Center Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Model Organisms Center Inc stock attractive at the current price?
The data as of Nov 7, 2026: price ¥44.33, calculated fair value ¥27.36 (−38%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688265 calculated?
We run Shanghai Model Organisms Center Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥27.36 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shanghai Model Organisms Center Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Model Organisms Center Inc (688265)?
The closing price on Nov 6, 2026 was ¥44.33. Our model-based fair value is ¥27.36, about 38% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Model Organisms Center Inc right now?
The price sits above even our optimistic bull case (¥30.60). The favourable scenario is already priced in. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shanghai Model Organisms Center Inc
How large is the market capitalisation of Shanghai Model Organisms Center Inc (688265)?
The market capitalisation of Shanghai Model Organisms Center Inc is 3.3B CNY (≈ $501M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Model Organisms Center Inc (688265)?
The price-to-sales ratio of Shanghai Model Organisms Center Inc is 7.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Model Organisms Center Inc (688265)?
Earnings per share at Shanghai Model Organisms Center Inc are ¥0.3100 (price ÷ EPS = P/E 143.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Model Organisms Center Inc (688265)?
The dividend yield of Shanghai Model Organisms Center Inc is 0.3% (payout 40.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Model Organisms Center Inc (688265)?
The net margin of Shanghai Model Organisms Center Inc is 4.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Model Organisms Center Inc (688265)?
The return on equity (ROE) of Shanghai Model Organisms Center Inc is 1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Model Organisms Center Inc (688265)?
On an EBIT basis the return on assets of Shanghai Model Organisms Center Inc is 0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Model Organisms Center Inc (688265)?
The operating margin of Shanghai Model Organisms Center Inc is −1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Model Organisms Center Inc (688265)?
Revenue at Shanghai Model Organisms Center Inc is growing +23.4% versus a year earlier (3y avg +11.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Model Organisms Center Inc (688265)?
Earnings per share at Shanghai Model Organisms Center Inc are growing −67.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shanghai Model Organisms Center Inc (688265) hold?
Shanghai Model Organisms Center Inc holds more cash than debt, 148M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shanghai Model Organisms Center Inc in the live analysis
One click puts Shanghai Model Organisms Center Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026